Related Experiment Video
Updated: Jan 15, 2026

The Application of Open Searching-based Approaches for the Identification of Acinetobacter baumannii O-linked Glycopeptides
Published on: November 2, 2021
Glycosylation-driven bioactivity switching: Comparative pharmacology and translational prospects of oroxin and
Huan Wang1, Yuan Liu1, Yi-Xuan Song1
1School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
Background:
Oroxin and its aglycone precursor, baicalein, are flavonoids with multi-target anticancer, anti-inflammatory, metabolic, and cardioprotective activities, yet clinical translation is hindered by poor bioavailability and insufficient toxicological data, particularly for oroxin.
Purpose:
To critically compare their molecular mechanisms, pharmacokinetics, and glycosylation-dependent activities, and to evaluate emerging production and delivery strategies that address translational barriers.
Methods:
Literature was identified through Web of Science and PubMed up to May 2025, using keywords ("Oroxin", "Baicalein", etc.) combined with pharmacological terms. The review prioritized original studies and reviews directly elucidating the compounds and comparing their activities or mechanisms. Studies lacking compound-specific or experimentally validated data were excluded. The included studies were categorized as in vitro or in vivo.
Results:
Both compounds context-dependently modulate PI3K/AKT, NF-κB, and endoplasmic reticulum stress pathways. Glycosylation in oroxin enhances aqueous solubility but reduces membrane permeability, thereby altering tissue distribution and metabolic stability. Baicalein undergoes extensive glucuronidation and exhibits a favorable safety margin, whereas oroxin lacks comprehensive toxicity profiling. Recent advances in microbial biosynthesis, chemoenzymatic synthesis, nanoformulations, and synergistic combinations have improved yield, absorption, distribution, metabolism, excretion properties, and therapeutic indices.
Conclusion:
While both oroxin and baicalein exhibit substantial therapeutic potential, their clinical application is limited by limited bioavailability and insufficient toxicological data, particularly in the case of oroxin. Ongoing and future research should prioritize the development of advanced drug delivery systems, robust safety evaluations, and deeper investigation into their synergistic and immunomodulatory effects to fully realize their clinical utility.
More Related Videos
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
13:35Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota
Published on: May 23, 2025
Related Concept Videos
Ligand Binding and Linkage
Oligosaccharide Assembly
Multiple sugar molecules that may or may...
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Protein Glycosylation
Glycosylation occurs in...
Drug Biotransformation: Overview
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...